{
    "clinical_study": {
        "@rank": "23320", 
        "arm_group": {
            "arm_group_label": "Tocilizumab", 
            "arm_group_type": "Other", 
            "description": "Biomarkers Measures\nAt the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the clinical response to IL-6 inhibition defined as\n      Low Disease Activity (DAS44) <2.4) at the follow-up visit at 12 months and the correlation\n      between the biomarkers and treatment response."
        }, 
        "brief_title": "Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis (RA)", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Signed informed consent form;\n\n          -  Patients aged 18 - 75 years;\n\n          -  RA classified in compliance with the 2010 ACR/EULAR criteria;\n\n          -  Patients that have to suspend a previous treatment with DMARDs for total\n             ineffectiveness or intolerance to drugs and/or patients that have not responded\n             adequately to first-line combination DMARDs / biological treatment;\n\n          -  Patients for which is indicated to start a treatment with an inhibitor of IL-6R for\n             high values indicative of systemic inflammation (ESR>=28 mm/hour, PCR>5 mg/l ,\n             Fibrinogen >400 mg/dl and or Albumin <3.5 g/dl) and high disease activity (DAS>2.4),\n             or contraindications to DMARDs use which make it necessary to take biological drug in\n             monotherapy.\n\n          -  Corticosteroids therapy stable (< = 7.5 mg)for at least four weeks;\n\n          -  Joint symptoms for at least three but no more than 24 months from the screening\n             visit;\n\n          -  DAS44 >2.4 and/or SDAI >11\n\n          -  Willing and able to comply with study procedures and timing.\n\n        Exclusion criteria:\n\n          -  On going pregnancy or lactation;\n\n          -  Severe active infections;\n\n          -  Patients with other clinically significant concomitant diseases whose treatment or\n             outcome could interfere with the expected evaluations of the study protocol.\n\n          -  Blood AST or ALT levels >5 times the upper normal limit;\n\n          -  ANC count <0.5 x 109/L\n\n          -  Platelet count <50 x103 /\u03bcL\n\n          -  Patients with other autoimmune rheumatic diseases, in addition to AR (for example\n             systemic lupus erythematosus [SLE], scleroderma, polymyositis, ecc\u2026)\n\n          -  Medical history or concomitant joint diseases in additions to AR (for example\n             tophaceous gout, reactive arthritis, psoriatic arthritis)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835613", 
            "org_study_id": "AR/BIOM"
        }, 
        "intervention": {
            "arm_group_label": "Tocilizumab", 
            "description": "At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.", 
            "intervention_name": "Biomarkers Measures", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Antirheumatic Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rheumatoid Arthritis", 
            "Early RA", 
            "RA", 
            "IL-6", 
            "IL-6R", 
            "Inhibitor", 
            "Inhibition", 
            "Tocilizumab", 
            "Biomarkers", 
            "DMARDs", 
            "Biological", 
            "DAS", 
            "SDAI", 
            "AR/BIOM", 
            "OEG"
        ], 
        "lastchanged_date": "April 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Roma", 
                    "country": "Italy"
                }, 
                "name": "Universit\u00e0 Cattolica del Sacro Cuore"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.", 
        "overall_contact": {
            "email": "info@oegisea.it", 
            "last_name": "Giovanni Lapadula, Prof.", 
            "phone": "+39 080 5478866"
        }, 
        "overall_official": {
            "affiliation": "Dipartimento di Reumatologia, Universit\u00e0 Cattolica del Sacro Cuore, Roma", 
            "last_name": "Gianfranco Ferraccioli, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease Activity Score (DAS-44)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Simplified Disease Activity Index (SDAI);Biomarkers Measures", 
                "safety_issue": "No", 
                "time_frame": "SDAI at 3-6-12-18 months"
            }, 
            {
                "description": "Evaluation by ELISA of the levels of the following biomarkers:\nIL-8, MCP-1, Chemerin, IL-1\u03b1, IL-1\u03b2, IL-17, IL-23, TGF\u03b21, IL-10, BAFF.in the plasma:", 
                "measure": "Biomarkers Measures", 
                "safety_issue": "No", 
                "time_frame": "Biomarkers Measures at 3-6-12-18 months"
            }
        ], 
        "source": "Osservatorio Epidemiologico GISEA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Osservatorio Epidemiologico GISEA", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}